About Us

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on two of the world’s most challenging conditions – Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor / Ataxia (FXTAS). There are no FDA approved treatments for the core symptoms of ASD and no FDA approved treatments at all for FXTAS. We exist in order to change that.

Management

Michael Derby, MS, MBA.png

Michael Derby

Howard Weisman

Zachary Rome.png

Zach Rome

Joseph Lucchese.png

Joseph Lucchese

David Hough.png

David Hough, MD

Board of Directors

Michael Derby, MS, MBA.png

Michael Derby

Howard Weisman

Zachary Rome.png

Zach Rome

Karen Dawes.png

Karen Dawes

3.png

Robert Apple

Paul K. Wotton

2.png

Karen LaRochelle

Advisory Board

Constance Smith-Hicks, MD, PhD

Reymundo Lozano, MD

Copy of Untitled Design-8.png

Alice Mao, MD

Michael Aman, PhD

Our Team

Partnerships

We are continuing to pursue opportunities to license or acquire additional late stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at info@paxmedica.com.

For patients needing more information, please contact: